Clinical Trials Sponsored by Otsuka Pharmaceutical, Inc., Philippines

Total 272 results

Otsuka Pharmaceutical, Inc., Philippines

Recruiting

"Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program" (RAISE)

Schizophrenia | Major Depressive Disorder

Philippines
Otsuka Pharmaceutical, Inc., Philippines

Completed

Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy

NSAID Induced Gastropathy

Philippines
Otsuka Pharmaceutical, Inc., Philippines

Completed

Study on the Efficacy and Safety of Oral Probucol Tablets in Patients With Hyperlipidemia - Post-Marketing Surveillance

Hyperlipidemia
Otsuka Pharmaceutical, Inc., Philippines

Completed

Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines (ASCEND)

Polyneuropathy

Philippines
Otsuka Pharmaceutical, Inc., Philippines

Completed

Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room

Asthma

Philippines
Otsuka Pharmaceutical, Inc., Philippines
Otsuka Pharmaceutical Co., Ltd.

Terminated

Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients

Pulmonary Disease, Chronic Obstructive

Philippines
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (SPRAY III)

Pain | Advanced Cancer

United States, Germany, United Kingdom, Mexico, Poland, Romania, Bulgaria, Czechia, Hungary, Puerto Rico
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Pain | Advanced Cancer

Israel, Italy, Taiwan, United Kingdom, Bulgaria, Hungary, India, Australia, Lithuania, Poland, Spain, Romania, Germany
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Pain | Advanced Cancer

Italy, United States, Taiwan, United Kingdom, Czechia, Bulgaria, Belgium, Latvia, Mexico, Lithuania, Poland, Romania, Hungary, Spain, Israel, Germany, Puerto Rico, Australia
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

Bipolar Disorder

United States, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Bipolar I Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in Patients With Acute Mania

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Schizophrenia Trial of Aripiprazole

Schizophrenia

Austria, United Kingdom, France, Spain, Sweden, Czech Republic, Denmark, Finland, Germany
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Patients With Bipolar I Disorder

Bipolar Disorder

France, Portugal, Spain, Italy, Germany, South Africa, United Kingdom, United States, Russian Federation, Poland, Czech Republic, Hungary, Netherlands, Estonia, Australia, Bulgaria, Switzerland
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Withdrawn

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Bipolar Disorder

United States, India
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

Bipolar Disorder

United States, South Africa, Brazil, Russian Federation, France, Czechia, Croatia, India, Bulgaria
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

Behavioral Symptoms | Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Behavioral Symptoms | Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

Dementia | Alzheimer's Disease

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Switch Study of BMS-337039 in Schizophrenic Out-patients

Schizophrenia

Belgium, Spain, Italy, Austria, Germany, France, Czech Republic, United Kingdom, Greece, Hungary
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients

Schizophrenia

Turkey, Austria, Germany, South Africa, Sweden, Finland, Czech Republic, Poland, France, Hungary, United Kingdom, Switzerland
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Patients With Acute Bipolar Mania

Bipolar Disorder

United States, Mexico, Peru, South Africa, Russian Federation, Croatia, Bulgaria
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

Schizophrenia | Schizoaffective Disorder

United States
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

Pain | Advanced Cancer

United States, United Kingdom, Bulgaria, Belgium, Poland, Hungary, Romania, Czechia, Puerto Rico, Lithuania, Germany, Latvia
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials

Schizophrenia

France, South Africa, Canada, Russian Federation, Poland, Czech Republic, Hungary, Croatia, Netherlands, Romania, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type

Dementia, Alzheimer Type
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

Bipolar Disorder Mania

Italy, Poland, Russian Federation, Turkey, South Africa, Austria, Hungary, France, Spain, Czech Republic, Germany, Greece, Romania
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Broad Effectiveness: Study With Aripiprazole

Schizophrenia | Schizoaffective Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Subjects With Alcoholism

Alcoholism

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder | Psychotic Disorder | Body Weight Change

United States, Brazil, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

Parkinson's Disease | Psychoses

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Effect on Cognitive Function of a Treatment With Aripiprazole

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

Schizophrenia

Belgium, France, Netherlands, Portugal, Spain
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices

Schizophrenia and Schizoaffective Disorder
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole Oral Acceptability Trial

Schizophrenia

United States
Otsuka Canada Pharmaceutical Inc.

Recruiting

Canadian Medical Assessment of JINARC™ Outcomes Registry (C-MAJOR)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Canada
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Withdrawn

Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability

Major Depressive Disorder and Irritability

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

MDD

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

Major Depressive Disorder (MDD)

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Outcomes in MEasurement-Based Treatment (COMET)

Depressive Disorder, Major
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

Inappropriate ADH Syndrome | Water Intoxication | Hyponatremias | Water-Electrolyte Imbalances

United States
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Development & Commercialization, Inc.

Recruiting

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Acute Schizophrenia

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity

Schizophrenia With Impulsivity

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO 2:4)

Polycystic Kidney, Autosomal Dominant

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Polycystic Kidney Disease, Autosomal Dominant

United States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany

Clinical Trials Sponsored by Otsuka Pharmaceutical, Inc., Philippines

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations